[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-458282-105":3,"detail-sidebar-cat-0-en-105":84,"doc-detail-458282-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":77,"head_meta":79,"extra_data":81,"updated_unix":83},105,"en","apoe-genotyping-and-12-month-longitudinal-tracking-of-p-tau217-using-fingerstick-collection-in-a-population-based-cohort","ApoE Genotyping and 12-Month Longitudinal Tracking of p-Tau217 Using Fingerstick Collection in a Population-Based Cohort","","Background: Implementing recently approved disease-modifying treatments for Alzheimer’s disease requires healthcare systems to adapt quickly. ApoE genotyping and measurement of phosphorylated tau at Thr217 (p-tau217) are essential for correct patient selection and monitoring treatment response. Here, the study evaluated simplified decentralized access using fingerstick sampling for ApoE genotyping and longitudinal plasma p-tau217 quantification from dried plasma spots.",{"@graph":14,"@context":76},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/apoe-genotyping-and-12-month-longitudinal-tracking-of-p-tau217-using-fingerstick-collection-in-a-population-based-cohort/458282/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/apoe-genotyping-and-12-month-longitudinal-tracking-of-p-tau217-using-fingerstick-collection-in-a-population-based-cohort/458282.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68,72],{"name":59,"@type":60,"acceptedAnswer":61},"What biomarkers were assessed in this study?","Question",{"text":62,"@type":63},"The study measured ApoE genotype and longitudinal plasma phosphorylated tau at Thr217 (p-tau217) using fingerstick-derived dried plasma spots.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were participants and samples collected over time?",{"text":67,"@type":63},"Participants provided dried plasma spots from on-site fingerstick collection at baseline (V0), 6 months (V6), and 12 months (V12), and paired venipuncture plasma samples were collected at each visit.",{"name":69,"@type":60,"acceptedAnswer":70},"What were the key findings regarding fingerstick sampling performance?",{"text":71,"@type":63},"p-tau217 levels from capillary dried plasma spots and plasma showed significant correlations across time points, and capillary dried plasma spots had good accuracy to discriminate based on cerebrospinal fluid Aβ status at multiple visits.",{"name":73,"@type":60,"acceptedAnswer":74},"What does the conclusion suggest for Alzheimer’s disease management?",{"text":75,"@type":63},"The results support fingerstick collection as a reliable, decentralized, temperature-independent approach to quantify p-tau217 longitudinally and genotype ApoE, potentially facilitating patient management.","https://schema.org",{"og:url":32,"og:type":78,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":80,"canonical":32},"index,follow",{"doc_id":82,"site_id":7},458282,1790752475,{"code":4,"msg":85,"data":86},"success",[87,91,95,99,104,109,113,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},"Exam",70,"exam",{"id":100,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},5,"Comic",60,"comic",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},6,"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":111,"slug":112},7,40,"healthcare",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},8,"Research & Report",30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":100,"slug":133},19,"General","general",{"code":4,"msg":85,"data":135},{"doc_id":82,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":110,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":83,"read_time":114,"preview_page_count":4},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","DOI: 10. 1002/alz70856_106796  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nApoE Genotyping and 12-Month Longitudinal Tracking of p-Tau217 Using Fingerstick Collection in a Population-Based Cohort  \nLaia Montoliu-Gaya1  Hanna Huber 1  Josep Blazquez2   \nLuisa Sophie Braun-Wohlfahrt3  Jakub Vávra3  Berta Calm4  Cañada Laia5  Amanda Cano5  Sergi Valero6  Victoria Fernández7  Kaj Blennow8  Henrik Zetterberg8  Mercè Boada9  Nicholas Ashton 10  Xavier Morató Arús6  \n1 Institute of Neuroscienace and Physiology, University of Gothenburg, Mölndal, Västra Götaland, Sweden  \n2Ace Alzheimer Center Barcelona, Barcelona, Spain, Spain  \n3 University of Gothenburg, Gothenburg, Sweden  \n4Ace Alzheimer Center Barcelona, Barcelona, Spain  \n5 Research Center and Memory Clinic, Fundació ACE Institut Català de Neurociències Aplicades-Universitat Internacional de Catalunya (UIC), Barcelona, Spain  \n6Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain  \n7Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Barcelona, Spain  \n8 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Västra Götalands län, Sweden  \n9 Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain  \n10 Banner Alzheimer’s Institute, Phoenix, AZ, USA  \nCorrespondence  \nLaia Montoliu-Gaya, Institute of Neuroscienace and Physiology, University of Gothenburg, Mölndal, Västra Götaland, Sweden.  \nEmail: [laia.montoliu.gaya@gu.se](laia.montoliu.gaya@gu.se)  \nAbstract  \nBackground: Implementing recently approved disease-modifying treatments for Alzheimer’s disease (AD) requires healthcare systems to adapt rapidly. ApoE genotyping and determination of phosphorylated tau at Thr217 (p-tau217) levels are essential for accurate patient selection and treatment response monitoring, respectively. Simplified, decentralized access to these biomarkers could reduce patient burden and healthcare resource consumption. Here, we evaluated the performance of fingerstick sampling for ApoE genotyping and longitudinal plasma p-tau217 quantification.  \nMethod: Participants were evaluated at the Memory Unit of Ace Alzheimer Center Barcelona and provided longitudinal dried plasma spots (DPS) from on-site fingerstick collection at baseline (V0), 6 months (V6), and 12 months (V12). Capillary DPS cards were shipped to Gothenburg, Sweden, within seven days, without temperature control or cooling, and processed using a custom extraction protocol. Paired venipuncture plasma samples were collected at each visit. p-tau217 levels were measured with the ALZpath Simoa assay. Cerebrospinal fluid (CSF) Aβ1-42/Aβ1-40 measurements were available for all participants. In a sub-cohort, an additional fingerstick sample was collected for ApoE genotyping, performed using real-time PCR.  \nResult: A total of 58 participants (mean age 75.0 years, 61% female, 38% ApoEε4 carriers) were included in the study. The levels of p-tau217 from capillary DPS and plasma samples showed significant correlations at the three time points (all p \u003C0.001). capillary DPSp-tau217 showed high accuracy to discriminate patients based on their CSFAβ status at V0 (AUC=0.83, CI95% 0.76-0.91), V6 (AUC=0.79, CI95% 0.67-0.91) and  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e106796.  \n[https://doi.org/10.1002/alz70856_106796](https://doi.org/10.1002/alz70856_106796)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of3  \nBIOMARKERS  \nV12 (AUC=0. 73, CI95% 0.63-0.82), similar to the paired plasma. Changes in capillary DPS and venous pl","cbCaiaMZO6p7UZhR","https://ap.wps.com/l/cbCaiaMZO6p7UZhR","pdf",632791,"English","# Abstract\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What biomarkers were assessed in this study?\",\"answer\":\"The study measured ApoE genotype and longitudinal plasma phosphorylated tau at Thr217 (p-tau217) using fingerstick-derived dried plasma spots.\"},{\"question\":\"How were participants and samples collected over time?\",\"answer\":\"Participants provided dried plasma spots from on-site fingerstick collection at baseline (V0), 6 months (V6), and 12 months (V12), and paired venipuncture plasma samples were collected at each visit.\"},{\"question\":\"What were the key findings regarding fingerstick sampling performance?\",\"answer\":\"p-tau217 levels from capillary dried plasma spots and plasma showed significant correlations across time points, and capillary dried plasma spots had good accuracy to discriminate based on cerebrospinal fluid Aβ status at multiple visits.\"},{\"question\":\"What does the conclusion suggest for Alzheimer’s disease management?\",\"answer\":\"The results support fingerstick collection as a reliable, decentralized, temperature-independent approach to quantify p-tau217 longitudinally and genotype ApoE, potentially facilitating patient management.\"}]","ApoE Genotyping and 12-Month Longitudinal Tracking of p-Tau217 Using Fingerstick Collection in a Population-Based Cohort | PDF"]